Follow
Sarah Pirrie
Sarah Pirrie
CRUK Clinical Trials Unit, University of Birmingham
Verified email at bham.ac.uk
Title
Cited by
Cited by
Year
Addressing overtreatment of screen detected DCIS; the LORIS trial
A Francis, J Thomas, L Fallowfield, M Wallis, JMS Bartlett, C Brookes, ...
European journal of cancer 51 (16), 2296-2303, 2015
3612015
The detection of hepatocellular carcinoma using a prospectively developed and validated model based on serological biomarkers
PJ Johnson, SJ Pirrie, TF Cox, S Berhane, M Teng, D Palmer, J Morse, ...
Cancer Epidemiology, Biomarkers & Prevention 23 (1), 144-153, 2014
2982014
Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen—To Offer More?(aTTom) trial
JMS Bartlett, DC Sgroi, K Treuner, Y Zhang, I Ahmed, T Piper, R Salunga, ...
Annals of Oncology 30 (11), 1776-1783, 2019
1642019
Clinical outcomes and survival following treatment of metastatic castrate-refractory prostate cancer with docetaxel alone or with strontium-89, zoledronic acid, or both: the …
ND James, SJ Pirrie, AM Pope, D Barton, L Andronis, I Goranitis, S Collins, ...
JAMA oncology 2 (4), 493-499, 2016
852016
Examining the immunological effects of COVID-19 vaccination in patients with conditions potentially leading to diminished immune response capacity–the OCTAVE trial
P Kearns, S Siebert, C Gaskell, A Kirkham, S Pirrie, S Bowden, ...
692021
Urinary EpCAM in urothelial bladder cancer patients: characterisation and evaluation of biomarker potential
RT Bryan, NJ Shimwell, W Wei, AJ Devall, SJ Pirrie, ND James, ...
British journal of cancer 110 (3), 679-685, 2014
542014
SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease
E Barnes, CS Goodyear, M Willicombe, C Gaskell, S Siebert, T I de Silva, ...
Nature medicine 29 (7), 1760-1774, 2023
532023
Protein shedding in urothelial bladder cancer: prognostic implications of soluble urinary EGFR and EpCAM
RT Bryan, HL Regan, SJ Pirrie, AJ Devall, KK Cheng, MP Zeegers, ...
British journal of cancer 112 (6), 1052-1058, 2015
472015
Targeted deep sequencing of urothelial bladder cancers and associated urinary DNA: a 23‐gene panel with utility for non‐invasive diagnosis and risk stratification
DG Ward, NS Gordon, RH Boucher, SJ Pirrie, L Baxter, S Ott, L Silcock, ...
BJU international 124 (3), 532-544, 2019
462019
Comparing an imaging-guided pathway with the standard pathway for staging muscle-invasive bladder cancer: preliminary data from the BladderPath study
RT Bryan, W Liu, SJ Pirrie, R Amir, J Gallagher, AI Hughes, KP Jefferson, ...
European urology 80 (1), 12-15, 2021
422021
Sarcomatoid renal cell carcinoma: clinical outcome and survival after treatment with sunitinib
V Kunene, M Miscoria, S Pirrie, MR Islam, M Afshar, E Porfiri
Clinical Genitourinary Cancer 12 (4), 251-255, 2014
422014
Clinical outcomes in patients with castrate-refractory prostate cancer (CRPC) metastatic to bone randomized in the factorial TRAPEZE trial to docetaxel (D) with strontium-89 …
ND James, S Pirrie, D Barton, JE Brown, L Billingham, SI Collins, ...
Journal of Clinical Oncology 31 (18_suppl), LBA5000-LBA5000, 2013
352013
Overall survival in men with bone metastases from castration-resistant prostate cancer treated with bone-targeting radioisotopes: a meta-analysis of individual patient data …
S Terrisse, E Karamouza, CC Parker, AO Sartor, ND James, S Pirrie, ...
JAMA oncology 6 (2), 206-216, 2020
342020
TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony …
N James, S Pirrie, A Pope, D Barton, L Andronis, I Goranitis, S Collins, ...
NIHR Journals Library, 2016
322016
The association between smoking cessation before and after diagnosis and non-muscle-invasive bladder cancer recurrence: a prospective cohort study
FHM van Osch, SHJ Jochems, RC Reulen, SJ Pirrie, D Nekeman, ...
Cancer Causes & Control 29, 675-683, 2018
302018
Results of a UK National Cancer Research Institute Phase II study of brentuximab vedotin using a response‐adapted design in the first‐line treatment of patients with classical …
A Gibb, SJ Pirrie, K Linton, V Warbey, K Paterson, AJ Davies, GP Collins, ...
British Journal of Haematology 193 (1), 63-71, 2021
232021
Breast Cancer Index is a predictive biomarker of treatment benefit and outcome from extended tamoxifen therapy: final analysis of the Trans-aTTom study
JMS Bartlett, DC Sgroi, K Treuner, Y Zhang, T Piper, RC Salunga, ...
Clinical Cancer Research 28 (9), 1871-1880, 2022
212022
Repurposed floxacins targeting RSK4 prevent chemoresistance and metastasis in lung and bladder cancer
S Chrysostomou, R Roy, F Prischi, L Thamlikitkul, KL Chapman, U Mufti, ...
Science translational medicine 13 (602), eaba4627, 2021
212021
A study of angiogenesis markers in patients with renal cell carcinoma undergoing therapy with sunitinib
C Stubbs, AD Bardoli, M Afshar, S Pirrie, M Miscoria, I Wheeley, E Porfiri
Anticancer research 37 (1), 253-259, 2017
192017
Predictive factors for response to abiraterone in metastatic castration refractory prostate cancer
M Afshar, F Al-Alloosh, S Pirrie, C Rowan, ND James, E Porfiri
Anticancer research 35 (2), 1057-1063, 2015
162015
The system can't perform the operation now. Try again later.
Articles 1–20